Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Pfizer and BioNTech have received fast track designation from the US Food and Drug Administration (FDA) for two of their four potential Covid-19 vaccines.
The two potential vaccines, BNT162b1 and BNT162b2, are part of the companies’ BNT162 mRNA-based vaccine programme. The candidates are currently in ongoing Phase I / II clinical trials in the US and Germany.
FDA granted the fast track designation after reviewing preliminary results from Phase I / II studies and also data from animal immunogenicity studies.